Strensiq 80 MG/0.8 ML INJ.
Active Awarded Last action
- Contract number
- 36C26026F0055
- Awardee
-
Alexion Pharmaceuticals Inc. UEI DKCXLGANZAN3
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,255,805
Award facts
- Contract value 100% obligated
- $1,255,804.80 Current and potential, with all options
- Completion date 85% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Carrollton, TX 75010, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $2,191 | |
| Original award | $1,253,613 |
About this award
Alexion Pharmaceuticals Inc. was awarded a delivery order valued at $1.26M by Veterans Integrated Service Network 20 for the supply of STRENSIQ 80 mg/0.8 mL injectable medication, including a 2026 price increase provision. The contract is firm fixed price with no set-aside designation, reflecting open competition procurement. This delivery order was awarded on December 22, 2025, with an ultimate completion date of December 21, 2026, and will be performed at Alexion's facility in Carrollton, Texas. The award operates under the Pharmaceuticals and Drugs General Services Administration Schedule (FSS-61-IB) and represents one of multiple delivery orders the Department of Veterans Affairs has issued to Alexion since August 2022.
STRENSIQ is a specialized therapeutic used to treat hypophosphatasia, a rare genetic disorder affecting pediatric and juvenile populations. This delivery order is issued under Alexion's existing single-award Blanket Purchase Agreement with the Department of Veterans Affairs National Acquisition Center, valued at $4.24M and active through August 31, 2026. The BPA mechanism enables Veterans Integrated Service Networks and individual VA medical facilities to place task orders as needed to ensure continuity of care for veterans requiring this rare disease treatment. Alexion, a Boston-headquartered biopharmaceutical company specializing in rare disease therapeutics, maintains active federal vendor status and has demonstrated sustained capability in delivering critical pharmaceutical products to the VA healthcare system.
Quick answers
Who was awarded contract 36C26026F0055?
36C26026F0055 was awarded to Alexion Pharmaceuticals Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on December 22, 2025.
How much is contract 36C26026F0055 worth?
The government has obligated $1,255,805 on 36C26026F0055.
Is contract 36C26026F0055 an order under another contract?
Yes. 36C26026F0055 is a delivery order under 36F79718D0355, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26026F0055 competed?
The extent of competition for 36C26026F0055 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award